North American Prodromal Synucleinopathy Consortium Stage 2

Part of paid clinical trials in Los Angeles, California.

Sponsor
Washington University School of Medicine
Study ID
NCT05826457
Status
Enrolling By Invitation

Conditions

  • Dementia With Lewy Bodies
  • Lewy Body Dementia
  • Multiple System Atrophy
  • Parkinson Disease
  • REM Sleep Behavior Disorder
  • REM Sleep Parasomnias

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

Key Dates

Start date
Aug 12, 2022
Status verified
May 2026
Primary completion
May 1, 2027
Completion
May 1, 2028

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: RBD group
    Clinical observation involving annual visits to a study site for up to 5 years.
  • Arm: control group
    Clinical observation involving annual visits to a study site for up to 5 years.

Primary Outcome Measure

Prodromal Synucleinopathy Rating Scale [ Time Frame: up to 5 years ]

Locations (8)

FacilityCityStateZIPSite coordinators
University of California Los AngelesLos AngelesCalifornia90095-
Stanford UniversityRedwood CityCalifornia94063-
Emory UniversityAtlantaGeorgia30322-
Massachusetts General HospitalBostonMassachusetts02145-
University of MinnesotaMinneapolisMinnesota55414-
Mayo Clinic RochesterRochesterMinnesota55905-
Washington University School of MedicineSt LouisMissouri63110-
Oregon Health Sciences UniversityPortlandOregon97239-

Find similar trials in Los Angeles, CA

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
University of California Los Angeles· Los Angeles, CAStanford University· Redwood City, CAEmory University· Atlanta, GAMassachusetts General Hospital· Boston, MAUniversity of Minnesota· Minneapolis, MNMayo Clinic Rochester· Rochester, MN

Related Studies